OvaScience Merging with Millendo to Focus on Treatments for Rare Endocrine Diseases, Including PWS
A merger between OvaScience and Millendo Therapeutics will focus on advancing Millendo’s pipeline of treatments for orphan endocrine diseases (diseases involving hormones), including Prader-Willi syndrome (PWS), according to a press release. The merged company will operate under the name Millendo Therapeutics. “We are excited about the opportunities created by…